Elacestrant: a new FDA-approved SERD for the treatment of breast cancer

被引：16

作者：

Bhatia, Neha ^{[1
]}

Thareja, Suresh ^{[1
]}

机构：

[1] Cent Univ Punjab, Sch Pharmaceut Sci, Dept Pharmaceut Sci & Nat Prod, Bathinda 151401, Punjab, India

来源：

MEDICAL ONCOLOGY | 2023年 / 40卷 / 06期

关键词：

Breast cancer; Elacestrant; Orserdu; SERD; Estrogen; RECEPTOR DEGRADERS SERDS; EVALUATING ELACESTRANT; ESTROGEN; FULVESTRANT; MANAGEMENT; AROMATASE;

D O I：

10.1007/s12032-023-02045-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu (R). Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrates the development stages of Elacestrant, with its medicinal chemistry, synthesis, mechanism of action, and pharmacokinetic studies. Clinical data and safety profile has also been discussed, including data from randomized trials.

引用

页数：8

共 60 条

[1] Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD [J].

Aftimos, P. G. ;

Cortes, J. ;

Bidard, F. C. ;

Kaklamani, V. ;

Bardia, A. ;

Neven, P. ;

Streich, G. ;

Montero, A. ;

Forget, F. ;

Reynier, M. A. Mouret ;

Sohn, J. ;

Taylor, D. ;

Harnden, K. ;

Khong, H. ;

Kocsis, J. ;

Dalenc, F. ;

Dillon, P. ;

Tonini, G. ;

Grzegorzewski, K. J. ;

Lu, J. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S638-S638

[2]

[Anonymous], 2023, STEML THER SUBS MEN

[3]

Arlt H, 2018, CANCER RES, V78

[4] Computer-Aided Ligand Discovery for Estrogen Receptor Alpha [J].

Bafna, Divya ;

Ban, Fuqiang ;

Rennie, Paul S. ;

Singh, Kriti ;

Cherkasov, Artem .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) :1-49

[5]

Bardia A, 2022, CANCER RES, V82, pGS2

[6] Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview [J].

Bhatia, Neha ;

Hazra, Shreejita ;

Thareja, Suresh .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256

[7] Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial [J].

Bidard, Francois-Clement ;

Kaklamani, Virginia G. ;

Neven, Patrick ;

Streich, Guillermo ;

Montero, Alberto J. ;

Forget, Frederic ;

Mouret-Reynier, Marie-Ange ;

Sohn, Joo Hyuk ;

Taylor, Donatienne ;

Harnden, Kathleen K. ;

Khong, Hung ;

Kocsis, Judit ;

Dalenc, Florence ;

Dillon, Patrick M. ;

Babu, Sunil ;

Waters, Simon ;

Deleu, Ines ;

Saenz, Jose A. Garcia ;

Bria, Emilio ;

Cazzaniga, Marina ;

Lu, Janice ;

Aftimos, Philippe ;

Cortes, Javier ;

Liu, Shubin ;

Tonini, Giulia ;

Laurent, Dirk ;

Habboubi, Nassir ;

Conlan, Maureen G. ;

Bardia, Aditya .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) :3246-+

[8]

Bihani T, ELACESTRANT RAD1901

[9]

Chemical S-S, 2022, EL DIH

[10] Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer [J].

Chen, Ya-Chi ;

Yu, Jiajie ;

Metcalfe, Ciara ;

De Bruyn, Tom ;

Gelzleichter, Thomas ;

Malhi, Vikram ;

Perez-Moreno, Pablo D. ;

Wang, Xiaojing .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (06) :515-529

← 1 2 3 4 5 6 →